Κατεύθυνση Οικονομία και Διοίκηση Υπηρεσιών Υγείας
Library of the Faculty of Economics and of the Faculty of Business Administration

2019-11-03

2019

Theodorakopoulos Georgios

Υφαντόπουλος Ιωάννης, Ομότιμος Καθηγητής, Τμήμα Πολιτικής Επιστήμης και Δημόσιας Διοίκησης, ΕΚΠΑ

Συστηματική ανασκόπηση κλινικής και οικονομικής επιβάρυνσης των βακτηριαιμιών που σχετίζονται με τους κεντρικούς καθετήρες παγκοσμίως: Μελέτη περίπτωσης Ελληνικών Μ.Ε.Θ

Greek

Systematic review of clinical and financial burden of catheter related bloodstream infections worldwide: A case study of Greek ICU's

The purpose of the study is to highlight the socio-economic impact (burden of disease) of CRBSI’s / CLABSI's. This is a systematic literature review that analyzes the clinical and financial burden of CRBSI’s / CLABSI’s worldwide and presents new, more cost-effective medical technologies with the help of econometric models. Altogether, in both search engines, 225 articles were identified after a keyword survey ‘’central line associated bloodstream infection OR catheter related bloodstream infection AND economic AND cost’’ during the 2010-2018 period and reported in clinical trials or patient control studies.
A total of 17 studies met the study inclusion criteria. It was found that the average cost of treatment of patients with CRBSI's / CLABSI's worldwide ranges from 11,200 € - 87,928 €. CRBSI's / CLABSI's are associated with a greater increase in mortality risk by 2.27 times and an increase in length of stay up to 19.6 days. A quality and infection prevention program such as the ICU Keystone project in the USA have been found to reduce incidence by 50% and mechanical complications by 25%.
In conclusion, the prevention of infections such as CRBSI's / CLABSI's can be made more effective by investing in new medical technologies such as antimicrobial I.V dressings with chlorhexidine in gel or sponge form. Introducing these in the clinical practice would reduce the incidence of episodes, length of hospitalization, and result in significant cost savings in both hospitals and health systems making them sustainable.
The added cost of new technologies can be absorbed by the introduction of new value-based care models as they provide mutual benefits to both payers (insurance, government) and healthcare providers (hospitals) by allowing them to see the benefits of a new treatment or technology and then compensate for it.

Health Sciences

central line associated bloodstream infection, catheter related bloodstream infection, economic, cost

No

0

Yes

41

81

https://pergamos.lib.uoa.gr/uoa/dl/object/2884674/file.pdf

https://pergamos.lib.uoa.gr/uoa/dl/object/2884674